Temporal associations between interleukin 22 and the extracellular domains of IL-22R and IL-10R2

J Li, KN Tomkinson, XY Tan, P Wu, G Yan… - International …, 2004 - Elsevier
J Li, KN Tomkinson, XY Tan, P Wu, G Yan, V Spaulding, B Deng, B Annis-Freeman…
International immunopharmacology, 2004Elsevier
Interleukin 22 (IL-22) is a cytokine induced during both innate and adaptive immune
responses. It can effect an acute phase response, implicating a role for IL-22 in mechanisms
of inflammation. IL-22 requires the presence of the IL-22 receptor (IL-22R) and IL-10
receptor 2 (IL-10R2) chains, two members of the class II cytokine receptor family (CRF2), to
effect signal transduction within a cell. We studied the interaction between human IL-22 and
the extracellular domains (ECD) of its receptor chains in an enzyme-linked …
Interleukin 22 (IL-22) is a cytokine induced during both innate and adaptive immune responses. It can effect an acute phase response, implicating a role for IL-22 in mechanisms of inflammation. IL-22 requires the presence of the IL-22 receptor (IL-22R) and IL-10 receptor 2 (IL-10R2) chains, two members of the class II cytokine receptor family (CRF2), to effect signal transduction within a cell. We studied the interaction between human IL-22 and the extracellular domains (ECD) of its receptor chains in an enzyme-linked immunoabsorbant assay (ELISA)-based format, using biotinylated IL-22 (bio-IL-22) and receptor-fusions containing the ECD of a receptor fused to the Fc of hIgG1 (IL-22R-Fc and IL-10R2-Fc). IL-22 has measurable affinity for IL-22R-Fc homodimer and undetectable affinity for IL-10R2. IL-22 has substantially greater affinity for IL-22R/IL-10R2-Fc heterodimers. Further analyses involving sequential additions of receptor homodimers and cytokine indicates that the IL-10R2ECD binds to a surface created by the interaction between IL-22 and the IL-22RECD, and thereby further stabilizes the association of IL-22 within this cytokine–receptor-Fc complex. Both a neutralizing rat monoclonal antibody, specific for human IL-22, and human IL-22BP-Fc, an Fc-fusion of the secreted IL-22 binding-protein and proposed natural antagonist for IL-22, bind to similar cytokine epitopes that may overlap the binding site for IL-22RECD. Another rat monoclonal antibody, specific for IL-22, binds to an epitope that may overlap a separate binding site for IL-10R2ECD. We propose, based on this data, a temporal model for the development of a functional IL-22 cytokine–receptor complex.
Elsevier